Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine Long-Term Extension in Japanese Children with ADHD
NCT00191386Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2005
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Primary endpoint: Adverse Events at 4 years. Started May 2005; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00191386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191386.